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Commentary
Current Controlled Trials: an opportunity to help improve the
quality of clinical research
Iain Chalmers
UK Cochrane Centre, NHS Research and Development Programme, Oxford, UK
Abstract
Some problems with the quality of controlled clinical trials can be addressed by following these
procedures: registering all trials at inception; using systematic reviews to inform the design of
new studies; posting and obtaining feedback on preprints; reporting all well conducted trials,
regardless of their results; reducing biased and inefficient assessment of reports submitted for
publication; publishing sufficiently detailed reports; linking trial reports to relevant external
information; providing readier access to reports; and reviewing and amending reports after initial
publication. The launch of a new range of electronic journals by Current Controlled Trials offers
an opportunity to contribute to progress in these ways. 
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What’s wrong with clinical research?
Six years ago Altman drew attention to “the scandal of
poor medical research” [1]. He called for less research,
better research, and research done for the right reasons.
In the continuing deluge of reports of biomedical research,
studies that really do seem to have been worth doing are
refreshing. The example I would single out from the field of
research in which I worked previously is the Collaborative
Eclampsia Trial [2]. The study showed that a dirt-cheap
drug (magnesium sulphate) was more effective than more
expensive alternatives in controlling convulsions in
eclampsia — a condition that leads to the deaths of about
50 000 women every year, almost all of them in develop-
ing countries. Not only did the trial demonstrate the great
importance of an inexpensive medicine that was not even
on WHO’s list of essential drugs, it also challenged
assumptions about the pathophysiology of convulsions
[3], prompting some neuroscientists to take a new interest
in the role of magnesium in seizure activity. Why are there
so few studies of this quality and relevance?
Failure to recognise controlled clinical trials as
‘indispensable ordeals’
One reason is that the need for reliable evaluation of clini-
cal interventions seems often to be overlooked in the
excitement surrounding more basic research. Fifty years
after the structure of DNA was discovered, for example,
the cacophony of claims about the potential benefits for
health care of this advance in basic knowledge is becom-
ing almost deafening. As one geneticist has observed,
however, “for twenty years geneticists have issued a
stream of promises about what they will achieve. Few have
been fulfilled, and some never will be” [4].
There is no way of responsibly bypassing the need to use
well-designed controlled clinical experiments to test theCurrent Controlled Trials in Cardiovascular Medicine    Vol 1 No 1 Chalmers
validity of therapeutic theories, whether these have been
derived from basic research, or from clinical impressions.
In a recently reported controlled trial of E5 murine mono-
clonal anti-endotoxin involving over 1100 patients, for
example, no benefit of this product could be detected,
despite the fact that basic understanding of Gram-nega-
tive sepsis has grown importantly over the past 20 years
[5]. A decade after the genetic defect leading to cystic
fibrosis was identified, people with the condition are
asking when they will see dividends to their health result-
ing from the discovery.
Very occasionally, the effects of new treatments are so
dramatic that carefully controlled research is unnecessary.
Usually, however, research designed to distinguish both
the effects of biases and the play of chance from treat-
ment effects is needed to protect the interests of patients.
These controlled clinical trials are ‘indispensable ordeals’
[6] for testing the validity of therapeutic hypotheses
derived from more basic research or clinical anecdote.
They are the principal means of ensuring that the health
care interventions on offer to the public are useful, and
that they are acceptably safe, at least in the short term.
Failure to study outcomes that matter to
patients
Not only must theories be validated in controlled trials,
they must be validated in ways that are meaningful to
patients. Psaty and his colleagues have drawn attention to
the need to study effects on outcome measures that
matter to patients and practitioners [7]. Reliance on surro-
gate outcomes sometimes has catastrophic conse-
quences. For example, as people who develop rhythm
abnormalities during heart attacks are more likely to die
prematurely, the demonstration that drugs could reduce
these arrhythmias was taken to be an important therapeu-
tic advance. Although Furberg, in an early systematic
review of the relevant controlled trials warned that a bene-
ficial effect of these drugs on mortality could not be
assumed [8], they continued to be used for nearly a
decade. At the peak of their use in the late 1980s, it has
been estimated that anti-arrhythmic drugs were causing
between 20 000 and 70 000 premature deaths every year
in the United States alone [9]. This yearly total of deaths is
of the same order of magnitude as the total number of
Americans who died in the Vietnam War.
Failure to cumulate the results of all well-
designed studies scientifically
The scale of this disaster might have been contained if
clinical researchers behaved in ways that acknowledge
that science is cumulative. Over 50 controlled trials of
anti-arrhythmic drugs were performed [10] before their
lethal capacity was finally acknowledged. That would not
have happened if clinical researchers, before embarking
on further studies, had routinely prepared or consulted
updates [11,12] of Furberg’s worrying systematic review
[8]. In addition, the lethal trend would have emerged
sooner if the results of new trials had been presented in
the context of an updated systematic review of all the
other relevant evidence from controlled trials. This process
is still extremely rare, even among reports of trials in the
most prominent general journals [13].
The scale of the anti-arrhythmic drug disaster might also
have been reduced if all the relevant research had been
published. In 1993, Cowley and his colleagues [14], com-
mendably, pointed out how an unpublished study per-
formed in 1980 might have “provided an early warning of
trouble ahead”. Nine patients had died among those
assigned to the anti-arrhythmic drug (lorcainide) com-
pared with only one patient among those assigned
placebo. “When we carried out our study in 1980”, they
reported, “we thought that the increased death rate was
an effect of chance…..The development of lorcainide was
abandoned for commercial reasons, and this study was
therefore never published; it is now a good example of
‘publication bias’”, the bias through which ‘negative’
results of research are less likely to be reported [15].
Acquiescence in distorted clinical research
agendas
Failure to publish the results of controlled trials for commer-
cial reasons is one of the reasons for growing doubts
about the integrity of clinical research. Recent commen-
taries in both The Lancet [16] and the New England
Journal of Medicine [17] have drawn attention to the wor-
rying incentives that drive those involved in clinical
research, and the increasingly dubious relationships that
are developing between academia and industry. One of the
editorialists asks bluntly ‘Is academic medicine for sale?’
Not only does the influence of industry within academia
raise worrying questions about the research that does get
done and reported; it also raises questions about the
research that does not get done. Commercial priorities
distort the ways in which inevitably limited clinical research
capacity is used. The ‘opportunity cost’ of this tendency is
that many questions about the effects of interventions
intended to improve health, particularly aspects of health
(such as eclampsia) in the poorer parts of the world [18],
may not be addressed because they do not interest the
commercial sector. Examples of issues of importance to
the public’s health include aspirin for myocardial infarction
[19], indomethacin for early dementia [20], corticosteroids
for head injury [21,22]; carotid endarterectomy for cerebral
ischaemia [23], investigations for benign chronic headache
[24], and counselling for psychological distress [25].
Commercial interests are not the only influences leading
to patterns of clinical research that do not serve the inter-
ests of patients. Perverse reward systems within academiac
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must share some of the responsibility. Relman, a former
editor of the New England Journal of Medicine, had this
scientifically bizarre advice for his readers: “Large-scale
multi-institutional clinical trials provide less opportunity for
authorship than individual or small-group research . . . .
Increased opportunities for authorship can be provided if
the National Institutes of Health encourage small-scale
clinical trials carried out by individual investigators.” [26].
Given the continuing problem of trials that are too small to
rule out effects of likely importance to patients, such
advice suggests a concern to ensure that, first and fore-
most, research should serve the interests of academic
investigators, not patients.
Other evidence that researchers do not have patients suf-
ficiently in mind when they design controlled trials comes
from the results of surveys to assess whether doctors
themselves would agree to participate in the trials to
which they are expected to recruit patients. For example,
asked whether they would consent to participate in each
of six lung cancer trials for which, as patients, they might
be eligible, between 36 and 89 per cent of a sample of
Canadian physicians who treat the disease said that they
would not participate [27].
How can electronic media be exploited to
improve the quality of clinical research?
Electronic publishing offers scope for improving the quality,
relevance and reporting of clinical research [28]. For the
reasons already noted, in no field of biomedical research is
improvement more important than in the design, conduct,
analysis and reporting of controlled trials. Guided by some
principles relevant to promoting the quality and relevance
of controlled trials, the new range of electronic journals
being launched by Current Controlled Trials thus offers an
important opportunity to contribute to progress.
Registering all controlled trials, at inception
The scientific and ethical reasons for prospective registra-
tion of controlled trials are now widely accepted [29–31].
Among the major international pharmaceutical companies,
Glaxo Wellcome has led the way in developing a disclo-
sure policy. The company has introduced a policy of regis-
tering information on its clinical trials programmes, and is
committed to publishing all clinical trials, and stating the
protocol number in every report of each trial, to avoid any
confusion and double counting [32].
There are three main reasons for requiring prospective reg-
istration of controlled trials. First, agencies that fund
research need to take their decisions in the light of informa-
tion about relevant ongoing research - to avoid duplication
of effort, to promote appropriate replication, and to promote
collaboration, for example, in multicentre trials and/or
prospective meta-analyses. Second, patients, clinicians and
other decision makers need to be informed about trials in
which they can participate, or to which they can contribute
in other ways. Third, people using evidence from controlled
trials to guide policies and practice, and decisions about
further research, need to be confident that they are aware of
all the trial evidence relevant to a particular question.
Working in collaboration with research funding organisa-
tions and others around the world, Current Controlled
Trials has established a meta-Register of Controlled Trials
[http://controlled-trials.com], and this now contains basic
details about thousands of ongoing controlled trials. In
addition, Current Controlled Trials has collaborated with
the UK’s Medical Research Council in piloting and estab-
lishing a system for assigning a unique identifier to each of
the trials registered in the meta-Register. Current Con-
trolled Trials will help investigators to ensure that trials are
registered and allocated an International Standard Ran-
domised Controlled Trial Number (ISRCTN), and this will
become a required component of all reports of trials pub-
lished in their journals. In addition, contact details for the
centres contributing to multicentre trials can also be pro-
vided on and after registration. Many of the trials in the
United States registered by CenterWatch [http://www.
centerwatch.com] and the National Institutes of Health
Clinical Trials Registry [http://clinicaltrials.gov] have sup-
plied this information, and Current Controlled Trials’ inter-
national  meta-Register of Controlled Trials will be
developed along these lines.
Given that some questionable methods are now used to
recruit patients to trials [33], it seems likely that groups
representing patients will increasingly insist on details of
ongoing trials being made publicly available, and that crite-
ria for consumer endorsement of and encouragement of
participation in particular trials will be developed and
applied. Indeed, I hope that a ‘Good Trials Guide’ will be
developed by groups representing the interests of con-
sumers. This might be a powerful lever in improving the
relevance of clinical trials to patients.
Using systematic reviews of existing trials to
inform the design of further trials
Consumer groups and others will wish know the extent to
which the design of a trial has taken account of the
results of systematic reviews of all relevant previous
research. This background information is required both
for scientific and for ethical reasons. Funding agencies
and research ethics committees have begun to require
those applying for support for new controlled trials to
refer to systematic reviews of relevant existing trials
[34,35]. Current Controlled Trials will establish links
between electronically held information about ongoing
controlled trials and relevant electronically published sys-
tematic reviews, for example, those published in The
Cochrane Library [http://www.update-software.com/
cochrane/cochrane-frame.html].Obtaining feedback on preprints of controlled
trials
Publication of preprints of research reports to obtain feed-
back has been commonplace for many years in some
spheres of scientific activity [36]. Although it is a relatively
new notion in clinical research, both the Lancet [37] and the
British Medical Journal [38] now offer a ‘preprint’ service to
the research community. Current Controlled Trials will also
provide a non-refereed preprint depository to which any
article can be submitted and which all individuals can
access free of charge. Any article can be submitted by its
authors, but they will remain responsible for the article’s
content. The only screening process will be to ensure rele-
vance of the article to the scope of Current Controlled
Trials and to avoid abusive, libellous or indecent articles.
Reporting all well-conducted controlled trials,
regardless of their results
Studies which have yielded ‘disappointing’ or ‘negative’
results are less likely to be presented at scientific meetings,
reported in print, published promptly, in full reports, in jour-
nals that are widely read, in English, and in more than one
report; and they are less likely to be cited in reports of later
studies [15]. On average, these reporting biases will tend
to lead to inferences that interventions are more effective
than they are in fact. Journals can help to reduce these
biases by requiring authors of reports of controlled trials to
state the trial registration details. In addition, although only
very basic information about a trial need be submitted to
achieve registration, this process offers an opportunity to
provide more details about studies. The Lancet, for
example, has pioneered journal peer review and publication
of trial protocols, undertaking to accelerate peer review of
reports of such trials on completion [39], a process that
will reduce result-dependent biases among reviewers.
Current Controlled Trials will offer a similar service.
One of the most important undertakings of Current Con-
trolled Trials is to publish all trials judged by peer review
to have been carried out correctly, irrespective of their
results. This undertaking is particularly important in
respect of reports of controlled trials that are ‘unexciting’,
but nevertheless can contribute, however modestly, to the
sum of knowledge relevant to a particular question.
Authors of reports of such trials often find themselves sub-
mitting to a succession of print journals, each of which
requires submissions in a slightly different format, only to
find that none of the journals is prepared to allocate their
limited page space to the studies concerned. Not surpris-
ingly, authors may stop trying to publish these studies. The
undertaking made by Current Controlled Trials will help to
reduce these unproductive efforts. This will be of particu-
lar help to pharmaceutical companies, which often under-
take routine or repetitive trials to fulfil regulatory
requirements. Several companies have recently committed
to publish results from all their trials by endorsing a set of
guidelines on Good Publication Practice [40], so develop-
ments that will facilitate this are particularly welcome.
Reducing biased and inefficient assessment of
trial reports submitted for publication
Contrary to widely held assumptions, the effectiveness of
the much vaunted ‘black box’ of peer review is not based
on empirical evidence supporting most of the various pro-
cedures and rituals which it comprises. Indeed, there is
evidence that the process can be biased [41]. Largely as
a result of initiatives taken under the aegis of the Journal
of the American Medical Association [42], there has been
an encouraging growth in the empirical research required
to sort out which of the elements of peer review are worth
retaining, and which should be jettisoned. Systematic
reviews of this evidence are being prepared (T Jefferson,
personal communication) and these will be used to inform
the procedures adopted by Current Controlled Trials.
Publishing sufficiently detailed reports of
controlled trials
A recurrent criticism of reports of controlled trials is that they
are not detailed enough to allow readers to judge the merit of
the research, or to apply it sensibly. The reporting guidelines
published by the CONSORT Group, and any revisions of
these [43], will be used as a basis for judging the acceptabil-
ity of submissions to Current Controlled Trials. Current Con-
trolled Trials are working towards providing authors with a
standard electronic template for reporting their studies to
help them comply with the guidelines. All articles accepted
for publication by Current Controlled Trials will be published
electronically without restrictions on length.
These electronically published reports will exploit all the
possibilities of this medium, including the opportunity to
publish large datasets and to display data in a form that
can be read directly by other software packages, to allow
readers to manipulate the data for themselves. Again,
other areas of scientific enquiry have been ahead of medi-
cine in depositing electronic datasets generated from
research, both for probity and to facilitate further analysis.
Such developments will clearly facilitate the more flexible
and robust meta-analyses that become possible using
individual patient data [44].
It will be possible to use large numbers of still illustrations,
for example, to describe the characteristics of patients
who participated in a particular trial, and also to publish
video illustrations, for example to show just what the inter-
ventions studied involved, and interviews with patients
about their experiences of these.
Linking trial reports to relevant external
information
Electronically published reports of controlled trials can be
linked to other relevant information held electronically. Most
Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 1 Chalmersobviously, links can be established with the bibliographic or
full text records of other studies cited in the report, and
with other reports of the same trial. In addition, because the
CONSORT guidelines state that data from a new trial
should be interpreted ‘in the light of the totality of the avail-
able evidence’ [43] and current reports of controlled trials
rarely do this [13], links can be made to relevant systematic
reviews. Furthermore, because many reports of trials end
with an indication of the important questions that remain
unanswered, links can be made to records of ongoing trials
that are addressing those questions.
In addition to these links of very direct relevance to the
report of a particular trial, considerable additional scope
exists for links to other material of possible relevance, such
as reports of similar trials, or background documents about
the health problems, interventions or outcomes studied.
Providing readier access to reports of
controlled trials
Although the World Wide Web has transformed access to
the results of research, in principle, 20th century publish-
ing norms mean that price barriers still stand between the
results of the research and those whose taxes, charitable
donations and expenditure on drugs have supported the
research. Current Controlled Trials believe that original
papers publishing information about trials should be free
to everyone. Research articles will therefore be available
free both on the Current Controlled Trials website and in
BioMed Central. This will help to make postpublication
peer review more effective, using facilities similar to the
BMJ’s Rapid Response System.
Reviewing and amending reports of controlled
trials after initial publication
Postpublication review of published reports of controlled
trials will sometimes uncover correctable errors, or the
need for more appropriate analyses. Improvement of trial
reports in response to these suggestions raises concerns
about what should be regarded as the ‘archival’ version of
a report, but this should not be a reason for failing to
improve a report when it is clear that this is possible. All the
pieces of information about and reports of a particular trial
will need to be electronically threaded together, so that
they can be assessed separately and together. As Tony
Johnson, formerly editor of Statistics in Medicine, said at a
meeting of the European Association of Science Editors:
“Current systems of peer review have failed to detect, let
alone correct, even elementary mistakes in design, analy-
sis, presentation and conclusions. Electronic publication
will enable us to move away from the single version,
printed paper, refereed by a small number of recognised
experts, to a dynamic multiversion paper which can be
updated as necessary to address criticisms of referees
throughout the world” [45].
Conclusions
Important progress was made during the 20th century in
developing robust research methods to assess the effects
of medical and other healthcare interventions. Very sub-
stantial room for improvement remains, however [46]. A
variety of strategies are required to improve matters so
that clinical research meets more effectively the needs of
people using the health services. Among these, electronic
publication of information about and derived from con-
trolled trials seems set to make an important impact.
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